969 related articles for article (PubMed ID: 23832540)
21. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
22. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Husu EN; Pitsillides C; Vesole S; Azab AK; Azab F; Melhem M; Ngo HT; Quang P; Maiso P; Runnels J; Liang MC; Wong KK; Lin C; Ghobrial IM
Blood; 2010 Jan; 115(3):559-69. PubMed ID: 19965685
[TBL] [Abstract][Full Text] [Related]
23. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
Kanteti R; Dhanasingh I; Kawada I; Lennon FE; Arif Q; Bueno R; Hasina R; Husain AN; Vigneswaran W; Seiwert T; Kindler HL; Salgia R
PLoS One; 2014; 9(9):e105919. PubMed ID: 25221930
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
26. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
27. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
Yang S; Xiao X; Meng X; Leslie KK
PLoS One; 2011; 6(10):e26343. PubMed ID: 22039466
[TBL] [Abstract][Full Text] [Related]
28. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK
PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
[TBL] [Abstract][Full Text] [Related]
30. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
31. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
32. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
33. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial transplantation inhibits cholangiocarcinoma cells growth by balancing oxidative stress tolerance through PTEN/PI3K/AKT signaling pathway.
Liu X; Zhang Y; Yang X; Zhang Y; Liu Y; Wang L; Yi T; Yuan J; Wen W; Jian Y
Tissue Cell; 2023 Dec; 85():102243. PubMed ID: 37865041
[TBL] [Abstract][Full Text] [Related]
35. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.
Lin G; Gai R; Chen Z; Wang Y; Liao S; Dong R; Zhu H; Gu Y; He Q; Yang B
Eur J Pharmacol; 2014 Apr; 729():45-53. PubMed ID: 24561043
[TBL] [Abstract][Full Text] [Related]
36. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
PeerJ; 2022; 10():e12750. PubMed ID: 35070505
[TBL] [Abstract][Full Text] [Related]
38. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
[TBL] [Abstract][Full Text] [Related]
39. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
40. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
